PE20151083A1 - Compuestos dimericos - Google Patents

Compuestos dimericos

Info

Publication number
PE20151083A1
PE20151083A1 PE2015000907A PE2015000907A PE20151083A1 PE 20151083 A1 PE20151083 A1 PE 20151083A1 PE 2015000907 A PE2015000907 A PE 2015000907A PE 2015000907 A PE2015000907 A PE 2015000907A PE 20151083 A1 PE20151083 A1 PE 20151083A1
Authority
PE
Peru
Prior art keywords
optionally substituted
alkyl
formula
aryl
cyano
Prior art date
Application number
PE2015000907A
Other languages
English (en)
Inventor
Steven Gregory Mischke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20151083A1 publication Critical patent/PE20151083A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/121,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se refiere a un compuesto dimerico de formula I o una sal farmaceuticamente aceptable del mismo, caracterizado porque Z es: (a) arilo opcionalmente sustituido con alcoxi C1-6, halogeno y alquilo C1-6; o (b) heteroarilo opcionalmente sustituido con arilo opcionalmente sustituido con ciano; X es alquilo C1-6, arilo opcionalmente sustituido con alquilo C1-6, heteroarilo, entre otros; Q es un resto de formula A o formula B; R1 es H o ciano; y R2 es alquilo C1-6 opcionalmente sustituido con arilo, cicloalquilo C3-7 opcionalmente fusionado con fenilo, fenilo o cicloalquilarilo C3-7. Dichos compuestos actuan como inhibidores de la union de la proteina SMAC a proteinas inhibidoras de apoptosis (PIA) y/o como inhibidores de la union de la proteina caspasa activada a las PIA, por lo cual resultan utiles en el tratamiento o control del cancer, especialmente de tumores solidos
PE2015000907A 2012-12-11 2013-12-09 Compuestos dimericos PE20151083A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261735684P 2012-12-11 2012-12-11

Publications (1)

Publication Number Publication Date
PE20151083A1 true PE20151083A1 (es) 2015-08-06

Family

ID=49726780

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000907A PE20151083A1 (es) 2012-12-11 2013-12-09 Compuestos dimericos

Country Status (19)

Country Link
US (1) US9409888B2 (es)
EP (1) EP2931719B1 (es)
JP (1) JP6309536B2 (es)
KR (1) KR20150093228A (es)
CN (1) CN104854100B (es)
AU (1) AU2013357493A1 (es)
CA (1) CA2887497A1 (es)
CL (1) CL2015001374A1 (es)
CO (1) CO7350640A2 (es)
CR (1) CR20150211A (es)
EA (1) EA201591024A1 (es)
HK (1) HK1213543A1 (es)
IL (1) IL238968A0 (es)
MA (1) MA38240B1 (es)
MX (1) MX2015007053A (es)
PE (1) PE20151083A1 (es)
PH (1) PH12015501088A1 (es)
SG (1) SG11201503718QA (es)
WO (1) WO2014090709A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲mPGES-1抑制劑之***酮化合物
EP2897972B1 (en) * 2012-09-19 2016-11-30 F. Hoffmann-La Roche AG 2-oxo-2,3,4,5-tetrahydro-1h-benzo[b]diazepines and their use in the treatment of cancer
CA2925084A1 (en) * 2013-11-18 2015-05-21 F. Hoffmann-La Roche Ag Tetrahydro-benzodiazepinones
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
CN108026017B (zh) * 2015-10-02 2021-09-21 日本瑞翁株式会社 酰卤溶液的制造方法、混合溶液及单酯化合物的制造方法
US10781205B2 (en) 2016-04-20 2020-09-22 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
WO2023031801A1 (en) 2021-09-01 2023-03-09 Novartis Ag Bifunctional degraders comprising a tead binder
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201402124A (zh) * 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
CN101861319B (zh) * 2007-11-16 2013-12-11 宇部兴产株式会社 苯并氮杂*酮化合物
US20110117081A1 (en) * 2008-05-05 2011-05-19 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
CA2789879A1 (en) * 2009-10-28 2011-05-19 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
EP2897972B1 (en) * 2012-09-19 2016-11-30 F. Hoffmann-La Roche AG 2-oxo-2,3,4,5-tetrahydro-1h-benzo[b]diazepines and their use in the treatment of cancer

Also Published As

Publication number Publication date
SG11201503718QA (en) 2015-06-29
US9409888B2 (en) 2016-08-09
MX2015007053A (es) 2015-09-28
AU2013357493A1 (en) 2015-04-30
PH12015501088A1 (en) 2015-08-03
CR20150211A (es) 2015-05-29
CL2015001374A1 (es) 2015-09-25
JP2016502986A (ja) 2016-02-01
EP2931719B1 (en) 2017-01-25
HK1213543A1 (zh) 2016-07-08
MA38240A1 (fr) 2018-02-28
CA2887497A1 (en) 2014-06-19
EP2931719A1 (en) 2015-10-21
CO7350640A2 (es) 2015-08-10
WO2014090709A1 (en) 2014-06-19
CN104854100B (zh) 2017-05-24
CN104854100A (zh) 2015-08-19
IL238968A0 (en) 2015-07-30
MA38240B1 (fr) 2018-09-28
EA201591024A1 (ru) 2015-09-30
US20160024055A1 (en) 2016-01-28
KR20150093228A (ko) 2015-08-17
JP6309536B2 (ja) 2018-04-11

Similar Documents

Publication Publication Date Title
PE20151083A1 (es) Compuestos dimericos
CY1124469T1 (el) Παραγωγα πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων
HUS2200010I1 (hu) Kondenzált heterociklusos vegyületek protein-kináz inhibitorként
UY34570A (es) Combinaciones de compuestos inhibidores de la proteína ns5a en el virus de hepatitis c
NI201600152A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
PE20170331A1 (es) Derivados quinolina como inhibidores smo
DOP2011000204A (es) Inhibidores de proteina cinasa
EA202090516A3 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
AR094918A1 (es) Compuestos de tetrahidropirrolotiazina como inhibidores de bace
SMT201500168B (it) Derivati di piperidinone come inibitori di mdm2 per il trattamento del cancro
AR082799A1 (es) Derivados de quinolina y quinoxalina como inhibidores de quinasa
PE20161073A1 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CL2014000905A1 (es) Compuestos derivados de acidos carboxilicos de carbamoil-hidroisoquinolinas sustituidas, inhibidores de proteinas antiapoptoticas bcl-xl; composicion farmaceutica; metodo de tratamiento para el cancer de mama, cancer de cuello uterino, cancer colorrectal, cancer hepatocelular, cancer de esofago, leucemias, mielomas, entre otros.
AR101367A1 (es) Pirimidinonas como inhibidores del factor xia
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
EA201591420A1 (ru) Гетероарильные соединения и их применение
EA201591745A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh
EA201592198A1 (ru) Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
EA201400735A1 (ru) Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201370211A1 (ru) Ингибиторы протеинкиназы
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201500875A1 (ru) СОЛИ ПРОИЗВОДНЫХ 2-АМИНО-1-ГИДРОКСИЭТИЛ-8-ГИДРОКСИХИНОЛИН-2-(1Н)-ОНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa

Legal Events

Date Code Title Description
FD Application declared void or lapsed